CD8A and neoplasm: In addition, in a phase I/II clinical trial of peptide vaccine IMA950/poly-ICLC for the treatment of malignant astrocytoma, Migliorini et al. found that 63.2% of patients showed tumor peptide-specific CD8+ T cell response, and 36.8% of patients showed polypeptide CD8+ T cell response [33].